Telix Pharmaceuticals and Grand Pharma Initiate Phase III Trial for Illucix in China
Australian biotechnology company Telix Pharmaceuticals Ltd (ASX: TLX) and its China market partner, Grand Pharmaceutical...
Mirxes Holding Company Receives FDA Breakthrough Device Designation for GASTROClea
Singapore-based RNA technology company, Mirxes Holding Company Ltd, which specializes in blood-based miRNA test kit...
China Unveils State Council Measures to Boost Foreign Direct Investment
The State Council of China has demonstrated its commitment to encouraging greater foreign investment by...
Bio-Thera Solutions’ BAT8006 Shows Positive Phase I Results in Solid Tumor Treatment
China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced positive Phase I clinical data for BAT8006...
Vcanbio Receives Orphan Drug Designation for VUM02 in Idiopathic Pulmonary Fibrosis Treatment
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that it has...
Asieris Pharmaceuticals’ Hexvix Meets Primary Endpoint in Phase III Bladder Cancer Study
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has revealed that a Phase III study...
Eli Lilly Completes Acquisition of Dice Therapeutics for $2.0 Billion
Pharmaceutical giant Eli Lilly (NYSE: LLY) has successfully concluded the purchase of US-based Dice Therapeutics...
Sichuan Kelun-Biotech’s SKB264 Achieves Primary Endpoint in Phase III TNBC Study
Sichuan Kelun Pharmaceutical Co., Ltd’s innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:...
Huadong Medicine’s HDM3001, a Biosimilar to Stelara, Accepted for Review by NMPA
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration...
Cascade Pharmaceuticals Secures RMB140 Million in Financing to Advance FXR Agonist Clinical Trials
Shanghai-based sino-foreign joint venture, Cascade Pharmaceuticals, Inc., has reportedly raised RMB140 million in a recent...
Migrasome Therapeutics Secures Over RMB100 Million in Angel+ Funding Round
Beijing-based biotech startup Migrasome Therapeutics has reported raising upwards of RMB100 million in its angel...
CanSino BiologicsLaunches Phase III Trial for DTcP Vaccine in Infants and Young Children
CanSino Biologics Inc. a leading China-based vaccines specialist (HKG: 6185), has announced the initiation of...
Hunan HSA Implements Direct BMI Fund Payments for VBP-Winning Drugs and Consumables
The Hunan Healthcare Security Administration (HSA) bureau has released a notice stating that effective from...
SAMR and Nine Ministries Tighten Regulations on Forums and Conferences in China
The State Administration for Market Regulation (SAMR) of China, in conjunction with nine other ministries,...
Cutia Therapeutics’ CU-10201 Enters Priority Review for Acne Treatment in China
Dermatology therapy developer Cutia Therapeutics (HKG: 2487) has announced that its CU-10201, a 4% minocycline...
Huadong Medicine Secures Exclusive Rights to Arcutis’ Daxas in Greater China and South-East Asia
Huadong Medicine Co., Ltd (SHE: 000963) has announced a significant licensing agreement with Arcutis (NASDAQ:...
Medtronic Partners with APMG to Advance Orthopedic Treatment Services in China
US-based Medtronic Inc., (NYSE: MDT) has entered into a partnership with China’s private healthcare group...
Everest Medicines and Shanghai Pharmaceuticals Deepen Partnership for Drug Distribution in China
China-based Everest Medicines (HKG: 1952) has announced a strategic partnership with Shanghai Pharmaceuticals marking a...
NMPA Greenlights Oricell Therapeutics’ OriCAR-017 for Clinical Trials in Multiple Myeloma
The National Medical Products Administration (NMPA) has indicated on its website that Oricell Therapeutics Co.,...
Beijing Balance Medical Receives Approval for Innovative Expandable Artificial Heart Valve in China
Beijing Balance Medical Technology Co., Ltd (SHA: 688198), a leading medical technology company in China,...